OncoMax presented its research at the 5th European Multidisciplinary Meeting for Urological Cancer (EMUC), which was held on 15-17 November 2013 in Marseille, France. Dr. Ilya Tsimafeyeu, a scientific advisor of OncoMax, has received a special award for the best research “FIRST PRIZE” for his study "FGF- and VEGF-dependent angiogenesis and its targeting".
The main activity of OncoMax, financed with by Maxwell Biotech Venture Fund, set up with the participation of RVC OJSC and RVC Seed Fund, is directed at development and bringing innovative biopharmaceutical medicines for diagnostics and treatment of oncological diseases to the international market.
The research has showed that bevacizumab and sunitinib - standard targeted therapy for the kidney cancer treatment - inhibit VEGF-induced angiogenesis but not FGF-induced angiogenesis. The active FGF-pathway leads to resistance development and tumor progression. Importantly, the research also has proved that FGF-induced angiogenesis can be blocked by OM-RCA-01 – monoclonal antibody to FGF-receprtor.
This elegant study has a great practical importance and answers the question how to overcome drug resistance in kidney cancer therapy,” – emphasized co-chairman of the Organizing Comittee Dr. Martin Spahn during the award presentation.
EMUC is an annual meeting organized by three European medical societies – the European Society for Medical Oncology (ESMO), the European Association of Urology (EAU) and the European Society for Radiotherapy and European Society for Radiotherapy and Oncology (ESTRO). The participants of this event are experts, clinical researchers and other professionals in the treatment of kidney cancer, bladder cancer and prostate cancer.
“We are pleased that the original Russian drug has been properly evaluated by the Organizing Committee of the EMUC-2013, one of the most significant events for the researches in the field of urological tumors, Ilya Tsimafeyeu mentioned, - We are planning to start the clinical study of OM-RCA-01 in the near future. The successful accomplishment of the clinical development program will enable us to bring a unique targeted anticancer drug that can improve the quality of patients’ life to international market.
The important research conducted by OncoMax has been supported by OncoMax investors – Maxwell Biotech Venture Fund, set up with the participation of RVC OJSC, and RVC Seed Fund.